Immediate Impact
1 by Nobel laureates 1 from Science/Nature 50 standout
Citing Papers
Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors
2025 Standout
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
2024 Standout
Works of Tunç Iyriboz being referenced
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Tunç Iyriboz | 83 | 150 | 190 | 111 | 16 | 461 | |
| Jennifer Ruhl | 50 | 142 | 290 | 89 | 12 | 556 | |
| Xiaoying Liu | 74 | 58 | 166 | 177 | 29 | 531 | |
| Michael Mazonakis | 142 | 116 | 106 | 65 | 17 | 448 | |
| Stephen Marcus | 23 | 91 | 88 | 51 | 33 | 512 | |
| Andrew Lesniak | 59 | 35 | 64 | 80 | 17 | 479 | |
| Premi Thomas | 70 | 43 | 154 | 164 | 15 | 486 | |
| Marla R. Hersh | 27 | 91 | 97 | 60 | 19 | 434 | |
| Fabiola Fernández‐Gutiérrez | 24 | 74 | 226 | 68 | 13 | 449 | |
| Dag Pavić | 157 | 163 | 172 | 24 | 30 | 541 | |
| William A. Chilcote | 218 | 242 | 60 | 45 | 21 | 565 |
All Works
Login with ORCID to disown or claim papers
Loading papers...